Chimerix Inc (CMRX): Ernest Mario , director of Chimerix Inc purchased 10,000 shares on May 13, 2016. The Insider buying transaction was reported by the company on May 16, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.53 per share for a total value of $45,328.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 11, 2016, Ernest Mario (director) purchased 25,000 shares at $4.80 per share price.On Mar 2, 2016, Timothy Wollaeger (director) purchased 10,000 shares at $4.61 per share price.Also, On Mar 2, 2016, Martha J Demski (director) purchased 10,000 shares at $4.89 per share price.On Dec 30, 2015, Clarence Patrick Machado (director) purchased 10,000 shares at $7.09 per share price.
Shares of Chimerix Inc (CMRX) ended Friday, May 13, 2016 session in red amid volatile trading. The shares closed down -0.02 points or -0.44% at $4.55 with 9,68,267 shares getting traded. Post opening the session at $4.56, the shares hit an intraday low of $4.46 and an intraday high of $4.68 and the price vacillated in this range throughout the day. The company has a market cap of $210 M and the number of outstanding shares has been calculated to be 4,62,13,134 shares. The 52-week high of Chimerix Inc is $58.04 and the 52-week low is $4.36.
Company has been under the radar of several Street Analysts.Chimerix Inc is Reiterated by FBR Capital to Mkt Perform while Lowering the Price Target of the company shares to $ 10 from a previous price target of $14 . The Rating was issued on Feb 23, 2016.Chimerix Inc is Downgraded by Morgan Stanley to Underweight. Earlier the firm had a rating of Equal-Weight on the company shares. The Rating was issued on Feb 23, 2016.Chimerix Inc is Downgraded by Barclays to Equal Weight while Lowering the Price Target of the company shares to $ 6 from a previous price target of $12 . Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Feb 23, 2016.Chimerix Inc is Downgraded by Citigroup to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Feb 22, 2016.
Chimerix Inc. a biopharmaceutical company dedicated to discovering developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound brincidofovir (BCV CMX001) which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient orally administered dosing regimens. In addition it has an active discovery program focusing on viral targets. CMX157 is its second clinical-stage nucleotide analog uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug tenofovir. Tenofovir marketed under the brand name Viread and in multiple fixed-dose combinations is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered developed and selected a clinical candidate CMX669 for BK virus and cytomegalovirus (CMV).